Your browser doesn't support javascript.
loading
Integrative Proteogenomics Using ProteomeGenerator2.
Kwok, Nathaniel; Aretz, Zita; Takao, Sumiko; Ser, Zheng; Cifani, Paolo; Kentsis, Alex.
Afiliação
  • Kwok N; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
  • Aretz Z; Doctor of Medicine Program, Weill Cornell Medicine, New York, New York 10065, United States.
  • Takao S; Department of Graduate Medical Education, HCA TriStar-Centennial Medical Center, Nashville, Tennessee 37203, United States.
  • Ser Z; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
  • Cifani P; Physiology Biophysics and Systems Biology Program, Weill Cornell Graduate School, Cornell University, New York, New York 10065, United States.
  • Kentsis A; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
J Proteome Res ; 22(8): 2750-2764, 2023 08 04.
Article em En | MEDLINE | ID: mdl-37418425
ABSTRACT
Recent advances in nucleic acid sequencing now permit rapid and genome-scale analysis of genetic variation and transcription, enabling population-scale studies of human biology, disease, and diverse organisms. Likewise, advances in mass spectrometry proteomics now permit highly sensitive and accurate studies of protein expression at the whole proteome-scale. However, most proteomic studies rely on consensus databases to match spectra to peptide and protein sequences, and thus remain limited to the analysis of canonical protein sequences. Here, we develop ProteomeGenerator2 (PG2), based on the scalable and modular ProteomeGenerator framework. PG2 integrates genome and transcriptome sequencing to incorporate protein variants containing amino acid substitutions, insertions, and deletions, as well as noncanonical reading frames, exons, and other variants caused by genomic and transcriptomic variation. We benchmarked PG2 using synthetic data and genomic, transcriptomic, and proteomic analysis of human leukemia cells. PG2 can be integrated with current and emerging sequencing technologies, assemblers, variant callers, and mass spectral analysis algorithms, and is available open-source from https//github.com/kentsisresearchgroup/ProteomeGenerator2.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteogenômica Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteogenômica Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article